Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00082394
Status:
COMPLETED
Last Update Posted:
2017-05-24
First Post:
2004-05-06
Brief Title:
A Study Comparing The Safety Tolerability and Efficacy of Trizivir VS Combivir Atazanavir In Subjects With HIV
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Phase IV Randomized Multicenter Open-Label Study to Compare the Safety Tolerability and Efficacy of Trizivir Abacavir 300mg Lamivudine 150mg and Zidovudine 300mg BID vs Combivir Lamivudine 150mg and Zidovudine 300mg BID Plus Atazanavir 400mg QD in Antiretroviral Naive HIV-1 Infected Subjects Over 48 Weeks
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study was to assess whether TRIZIVIR administered twice-daily was as safe tolerable and efficacious as a combination of the drugs COMBIVIR administered twice-daily and atazanavir administered once daily Over the course of 48 weeks various parameters that measure safety tolerability and efficacy of the investigational drugs were measured and compared
Detailed Description:
A Phase IV Randomized Multicenter Open-Label Study to Compare the Safety Tolerability and Efficacy of Trizivir abacavir 300mg lamivudine 150mg and zidovudine 300mg BID vs Combivir lamivudine 150mg and zidovudine 300mg BID plus atazanavir 400mg QD in Antiretroviral Naive HIV-1 Infected Subjects over 48 Weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None